Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 3/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428216 | 0.91 | PLG (0.40) | PLGPLAUF2ST14F10 | |
| SCHEMBL15406855 | 0.89 | PLG (0.37) | PLGPLAUF2ST14HDAC3 | |
| SCHEMBL21690009 | 0.89 | PLG (0.37) | PLGPLAUF2ST14HDAC3 | |
| SCHEMBL20561401 | 0.89 | PLG (0.37) | PLGPLAUF2ST14HDAC3 | |
| SCHEMBL29401470 | 0.89 | PLG (0.37) | PLGPLAUF2ST14HDAC3 | |
| Hydrochloric Acid SCHEMBL16893616 | 0.88 | PLG (0.37) | PLGPLAUF2ST14HDAC3 | |
| Hydrochloric Acid SCHEMBL4994024 | 0.88 | PLG (0.37) | PLGPLAUF2ST14HDAC3 | |
| SCHEMBL29401478 | 0.87 | PLG (0.39) | PLGPLAUF2ST14HDAC3 | |
| SCHEMBL29358214 | 0.87 | PLG (0.35) | PLGPLAUF2ST14HDAC3 | |
| SCHEMBL16893905 | 0.86 | PLG (0.37) | PLGPLAUF2ST14HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024083220-A1 | LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE | 上海京新生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11957787-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240117363-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| WO-2024043250-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024043249-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-11761007-B2 | Production of unnatural nucleotides using a CRISPR/Cas9 system | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-19 | — | — | US | disclosed |
| US-20160101145-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160052970-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-9096684-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8987414-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957787-B2 | Wnt compositions and methods for purification | WNT3A, CTNNBL1, WNT1 | PLG 1197/4885PLAU 1868/4885F2 4680/4885 |
| US-20160101145-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | PLG 2562/4885PLAU 2259/4885F2 3230/4885 |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | CD4, ICOS, NFATC1 | PLG 3996/4885PLAU 3594/4885F2 3360/4885 |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | GSTK1, GSTA2, GSTA1 | PLG 4142/4885PLAU 4369/4885F2 3161/4885 |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | ILK, EPCAM, MMP8 | PLG 354/4885PLAU 71/4885F2 2360/4885 |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | PLG 2025/4885PLAU 2445/4885F2 2798/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | PLG 1437/4885PLAU 671/4885F2 2487/4885 |
| US-20160052970-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | HIF1A, HIF1AN, EGLN3 | PLG 1977/4885PLAU 2190/4885F2 3942/4885 |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | RNGTT, MAX, POLRMT | PLG 3503/4885PLAU 3166/4885F2 3231/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | PLG 995/4885PLAU 1595/4885F2 769/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | PLG 676/4885PLAU 374/4885F2 3155/4885 |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | PLG 995/4885PLAU 1595/4885F2 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.